Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

Clinical trial NCT01082926 · COMPLETED

Trial details

NCT number: NCT01082926
Sponsor: City of Hope Medical Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Anaplastic Astrocytoma Anaplastic Ependymoma Anaplastic Meningioma Anaplastic Oligodendroglioma Brain Stem Glioma Ependymoblastoma Giant Cell Glioblastoma Glioblastoma Gliosarcoma Grade III Meningioma Meningeal Hemangiopericytoma Mixed Glioma

Start date: 2010-05-01
Primary completion: 2013-09-01
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.